A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
NCT06010329
This study is recruiting at 6 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Teligene US
- Last updated on ClinicalTrials.gov
- April 24, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California San Diego Moores Cancer Center · La Jolla, CA
Florida · 1
- Moffitt Cancer Center · Tampa, FL
Georgia · 1
- University Cancer & Blood Center (UCBC) - Athens · Athens, GA
Iowa · 1
- Mission Cancer + Blood - Mission Cancer Foundation · Des Moines, IA
New York · 1
- Perlmutter Cancer Center - 34th Street · New York, NY
Texas · 1
- University of Texas MD Anderson Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.